Brief: Integragen confirms MIR-31-3P biomarker predicts effects of cetuximab patients with metastatic colorectal cancer

IntegraGen SA

30/09/2014 07:04

Sept 30 (Reuters) - Integragen SA  ALINT.PA : 
    * Presents data confirming that MIR-31-3P biomarker predicts 
effects of cetuximab patients with metastatic colorectal cancer 
    * Says it has exclusive global license for MIR-31-3P 
 
Source text for Eikon:  ID:nBwbtzxsxa  
Further company coverage:  ALINT.PA  
 
 (Gdynia Newsroom: +48 58 698 39 20; 
Gdynia.newsroom@thomsonreuters.com) 
 
Keywords: INTEGRAGEN/BRIEF